BriaCell Therapeutics announced the successful pricing of a best-efforts public offering of 5,366,726 units, generating gross proceeds of approximately $30 million before placement agent fees and offering expenses. Each unit comprises one common share (or, at the purchaser’s election, a pre-funded warrant) and one warrant. The warrants have been approved for listing on the Nasdaq Capital Market under the symbol “BCTXL” and are exercisable immediately for a five-year term. The offering, arranged solely by ThinkEquity, is expected to close on January 15, 2026, subject to customary closing conditions. Net proceeds will be deployed to support BriaCell’s working capital requirements, general corporate purposes, and advancement of its immunotherapy pipeline.

In a Phase 1/2a trial of Bria-OTS, BriaCell’s personalized off-the-shelf immunotherapy for metastatic breast cancer, a 78-year-old patient with hormone receptor-positive, HER2-negative disease achieved a 100% resolution of a lung metastasis. This complete response was first observed after two months of monotherapy and has been confirmed at subsequent assessments at four, six and eleven months. The patient completed 17 treatment cycles with no dose-limiting toxicities and maintains stable disease at all other evaluable sites. With Phase 1 dose escalation now complete, BriaCell has initiated the Phase 2a expansion cohort combining Bria-OTS with an immune checkpoint inhibitor to further explore safety and efficacy in this heavily pretreated population.

Following the offering and bolstered by the ongoing clinical progress of BriaCell’s lead programs, management intends to allocate net proceeds primarily to fund continued clinical development of Bria-OTS and other pipeline candidates, scale manufacturing capacity for personalized immunotherapies, and support general corporate operations. These investments aim to position BriaCell to meet upcoming clinical milestones, including data readouts from the checkpoint inhibitor combination arm and enrollment completion in the monotherapy cohort.

By listing its warrants on Nasdaq and leveraging the TSX exemption for interlisted issuers, BriaCell enhances its access to North American capital markets while maintaining compliance with both U.S. and Canadian regulatory standards. The dual-listing strategy and fresh capital infusion are expected to broaden the shareholder base, improve trading liquidity for the company’s securities, and underpin future equity or strategic partnership transactions as BriaCell advances its novel immunotherapy platform toward registrational trials.